All In Biotech

Drug Trial Radar · NCT02435173

Study of Efficacy of CDZ173 in Patients With APDS/PASLI

An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Randomized, Subject, Investigator and Sponsor Blinded Placebo Controlled Study to Assess the Efficacy and Safety of CDZ173 (Leniolisib) in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/ p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)

Last checked: Nov 20, 2026Latest source record: Aug 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

37

Actual

Start

Aug 24, 2015

Primary completion

Aug 16, 2021

Study completion Aug 16, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 6, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to explore CDZ173, a selective PI3Kδ inhibitor, in patients with genetically activated PI3Kδ, i.e., patients with Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency (APDS/PASLI). The study consisted of two parts: Part I was the open label part designed to establish the safety and pharmacokinetics of CDZ173 in the target population, as well as to select the optimal dose to be tested in Part II. Part II was designed to assess efficacy and safety of CDZ173 in the target population.

Conditions

  • Common Variable Immunodeficiency (CVID), APDS / PASLI

Interventions

  • CDZ173Drug

    CDZ173 10 and 70 mg capsules for oral administration.

  • PlaceboOther

    Placebo capsules for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From the start of treatment to 30 days after end of treatment, assessed up to maximum duration of 114 days
  2. Part I: CDZ173 Dose ConcentrationTime frame: Days 1, 29 and 57 (0.25 and 3 h post morning dose) and Day 84
  3. Part I: Percentage of Inhibition of Unstimulated and Stimulated pAkt Levels in B CellsTime frame: Baseline, days 29 and 57 (3 and 12 h post-dose) and day 84
  4. Part II: Change From Baseline in the log10 Transformed Sum of Product of Diameters (SPD) in the Index LesionsTime frame: Baseline and Day 85
  5. Part II: Change From Baseline in Percentage of naïve B Cells Out of Total B CellsTime frame: Baseline and Day 85

Locations

10 sites in 9 countries. Site status is shown where the registry gives one.

  • National Institute of Health NIH

    Bethesda, Maryland

  • Novartis Investigative Site

    Minsk, Belarus

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Dublin, Ireland

  • Novartis Investigative Site

    Brescia, Italy

  • Novartis Investigative Site

    Palermo, PA, Italy

  • Novartis Investigative Site

    Rotterdam, Netherlands

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Belfast, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.